Home › Funds › GENERAL AMERICAN INVESTORS CO INC › REGN
GENERAL AMERICAN INVESTORS CO INC position in REGN
REGENERON PHARMACEUTICALS · Health Care
GENERAL AMERICAN INVESTORS CO INC reported holding 36,362 shares of REGN (REGENERON PHARMACEUTICALS) in its Q3 2026 13F filing — a position valued at US$27.6M, representing 1.74% of its reported portfolio and ranking #19 among its reported holdings. GENERAL AMERICAN INVESTORS CO INC has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How GENERAL AMERICAN INVESTORS CO INC's REGN position evolved
GENERAL AMERICAN INVESTORS CO INC first disclosed a stake in REGN in Q3 2023 at 16,576 shares (US$13.6M). The position peaked in Q3 2026 at 36,362 shares, worth US$27.6M. Across 13 filings, GENERAL AMERICAN INVESTORS CO INC increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 36,362 shares valued at US$27.6M. Notable position changes include a 25% increase in Q4 2024 (shares fell 11% over the following quarter), a 34% trim in Q2 2025 (shares rose 8% over the following quarter), a 218% increase in Q3 2025 (shares rose 36% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 16.58K | $13.64M | New |
| Q4 2023 | 16.58K | $14.56M | Hold |
| Q1 2024 | 14.58K | $14.03M | Reduce |
| Q2 2024 | 14.58K | $15.32M | Hold |
| Q3 2024 | 11.88K | $12.48M | Reduce |
| Q4 2024 | 14.88K | $10.60M | Add |
| Q1 2025 | 14.88K | $9.43M | Hold |
| Q2 2025 | 9.88K | $5.18M | Reduce |
| Q3 2025 | 31.36K | $17.63M | Add |
| Q4 2025 | 31.36K | $24.21M | Hold |
| Q1 2026 | 31.36K | $24.23M | Hold |
| Q2 2026 | 36.36K | $22.67M | Add |
| Q3 2026 | 36.36K | $27.57M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About REGN and 13F data
REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 29 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), Franklin Resources (US$2.75B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding REGN
- Dodge & Cox 4.87M sh · $3.04B · Q2 2026
- DODGE & COX 4.87M sh · $3.04B · Q2 2026
- Franklin Resources 2.95M sh · $2.75B · Q3 2026
- Nuveen, LLC 1.96M sh · $1.48B · Q3 2026
- LOOMIS SAYLES & CO L P 1.72M sh · $1.30B · Q3 2026
More on GENERAL AMERICAN INVESTORS CO INC
FAQ
How long has GENERAL AMERICAN INVESTORS CO INC held REGN?
GENERAL AMERICAN INVESTORS CO INC has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is GENERAL AMERICAN INVESTORS CO INC's current position in REGN?
As of Q3 2026, GENERAL AMERICAN INVESTORS CO INC holds 36.36K shares of REGN (REGENERON PHARMACEUTICALS), valued at $27.57M, representing 1.74% of its reported portfolio and ranking #19.
Has GENERAL AMERICAN INVESTORS CO INC been buying or selling REGN?
In the latest 13F filing (Q3 2026), GENERAL AMERICAN INVESTORS CO INC held unchanged its position in REGN. The position peaked in Q3 2026 at 36.36K shares.
Which other funds hold REGN?
Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, Franklin Resources, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.